“…Subsequent to a randomized, double-blind, placebo-controlled trial in 1986, the first-generation antipsychotic trifluoperazine was given FDA approval for short-term treatment of generalized non-psychotic anxiety (Gao, Muzina, Gajwani & Calabrese, 2006). Specifically, antipsychotics may be beneficial in OCD, which many have noted shares some features of a psychotic or delusional process (Bellino, Patria, Ziero & Bogetto, 2005;Kozak & Foa, 1994;Rodowski, Cagande & Riddle, 2008). Patients with OCD have classically had insight into the illogical nature of their thoughts or behaviors; the criteria for OCD in the current version of the Diagnostic and Statistical Manual of Mental Disorders includes that the patient recognizes the obsessions or compulsions are excessive or unreasonable, although this does not apply to children (DSM-IV-TR; APA, 2000).…”